Earnings call transcript: Nasdaq tops Q3 2026 estimates as stock rises premarket

Earnings call transcript: Nasdaq tops Q3 2026 estimates as stock rises premarket

Earnings call transcript: Nasdaq tops Q3 2026 estimates as stock rises premarket
These investments have a tendency to crash and burn
Mortgage performance continues to improve in the third quarter, as delinquencies declined across all stages in July, a new industry report found. Processing Content The national delinquency rate dropped 16 basis points to 3.39% last month, Intercontinental Exchange’s latest first look report found. The rate was still 12 basis points above last year but 46…
Public markets have rewarded investors handsomely over the past 15 years. Strong earnings, dominant technology companies and abundant liquidity helped drive stocks steadily higher. That run has also pushed valuations to historically demanding levels. U.S. stocks are now more expensive relative to the economy than they were during the dot-com bubble or the 2021 market…
Marex Group said Monday that it has agreed to acquire Brainchild Capital Investments, a Netherlands-based clearing and execution business. The acquisition extends the financial services platform’s reach into derivatives and physical markets in power and gas. BCI operates across energy and environmental markets, including physical delivery and hedging capabilities in power and gas. The company was…
FTSE Nareit All Equity REITs Index total returns were up about 20% year-to-date as of late last week, boosted by a strong July, with total returns up nearly 5% for the month. That compares with a roughly 9% year-to-date gain for the S&P 500 over the same period. The results have helped narrow a gap…
SHANGHAI, Aug. 11, 2026 /PRNewswire/ — Laekna (2105.HK) announced today that the New Drug Application (NDA) for LAE002 (afuresertib) has been accepted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer (LA/mBC) with PIK3CA/AKT1/PTEN alterations, following recurrence…